UCLA Researchers have identified a novel pharmacological target for hematopoietic stem cell regeneration. They have developed small molecule inhibitors against the target and shown that the inhibitors cause rapid stem cell regeneration.
Depletion of white and red blood cells also known as Myelosuppression is a common side effect of chemotherapy and radiotherapy. Currently, one FDA approved growth factor is used that increases white blood cell count but there are no therapies for total blood cell regeneration. Hematopoietic stem cells (HSCs) offer an alternative therapy, as they are a reservoir of both white and red blood cells. However, the mechanistic details of factors that govern HSC regeneration and proliferation are not known and no therapeutics that can increase HSC regeneration are available.
UCLA researchers in the Departments of Medicine and Chemistry and Biochemistry have identified a novel receptor, Protein tyrosine phosphatase sigma (PTPS) expressed on hematopoitic stem cells. They have characterized the mechanism extensively in vivo by knockout studies and found that PTPS regulates HSC regeneration. Based on their discovery, they have developed novel inhibitors targeting PTPS that cause dramatic hematopoitic stem cell regeneration in mice models and significantly improve the life span in mice receiving fatal irradiation.
|United States Of America||Issued Patent||10,822,299||11/03/2020||2016-518|
Hematopoietic stem cells, HSC, stem cells, long-term regeneration, HSC transplantation, protein tyrosine phosphatases, PTP, PTPS, myelosuppression, cancer, anemia